BioNTech SE

( )
BNTX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -0.37%333.610.0%$4529.69m
NVAXNovavax, Inc. -3.43%160.5579.4%$722.22m
BNTXBioNTech SE 0.67%262.850.0%$709.55m
AMGNAmgen, Inc. 1.80%206.781.4%$547.92m
SNSSSunesis Pharmaceuticals, Inc. -1.92%6.140.7%$429.21m
REGNRegeneron Pharmaceuticals, Inc. 1.59%552.112.7%$426.22m
GILDGilead Sciences, Inc. 1.52%66.901.0%$414.02m
CCXIChemoCentryx, Inc. 3.76%33.652.9%$399.69m
ILMNIllumina, Inc. 0.87%414.083.3%$377.90m
XLRNAcceleron Pharma, Inc. 0.43%173.745.3%$364.00m
VRTXVertex Pharmaceuticals, Inc. 2.55%185.411.9%$264.85m
BIIBBiogen, Inc. -0.59%268.131.7%$232.27m
OCGNOcugen, Inc. 0.85%8.330.0%$180.05m
XENEXenon Pharmaceuticals, Inc. -2.96%29.810.4%$166.66m
DNAGinkgo Bioworks Holdings, Inc. 20.21%14.810.0%$162.54m

Company Profile

BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. It exploits an array of discovery and therapeutic drug platforms for the development of novel biopharmaceuticals. The company's portfolio of infectious disease and oncology product candidates include FixVac, iNeST (Individualized Neoantigen Specific Immunotherapy), Intratumoral Immunotherapies, RiboMabs, RiboCytokines, CAR T Cell Platform, T Cell Receptor(TCR), Checkpoint Immunomodulator, Targeted Cancer Antibodies, and Small Molecule Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.